Literature DB >> 21257259

Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models.

Thomas C Chen1, Weijun Wang, Encouse B Golden, Simmy Thomas, Walavan Sivakumar, Florence M Hofman, Stan G Louie, Axel H Schönthal.   

Abstract

The alkylating agent temozolomide, in combination with surgery and radiation, is the current standard of care for patients with glioblastoma. However, despite this extensive therapeutic effort, the inclusion of temozolomide extends survival only by a few short months. Among the factors contributing to chemoresistance is elevated expression of the endoplasmic reticulum (ER) chaperone GRP78 (glucose-regulated protein 78; BiP), a key pro-survival component of the ER stress response system. Because the green tea component EGCG (epigallocatechin 3-gallate) had been shown to inhibit GRP78 function, we investigated whether this polyphenolic agent would be able to increase the therapeutic efficacy of temozolomide in preclinical models of glioblastoma. Mice with intracranially implanted human U87 (p53 wild type) or U251 (p53 mutant) glioblastoma cells were treated with temozolomide and EGCG, alone and in combination. We found that EGCG alone did not provide survival benefit, but significantly improved the existing therapeutic effect of temozolomide, i.e., life extension was substantially greater under combination therapy as compared to temozolomide therapy alone. Immunohistochemical analysis of tumor tissue revealed increased expression levels of GRP78 in temozolomide-treated animals, which was diminished when temozolomide was combined with EGCG. Parallel in vitro experiments with siRNA targeting GRP78 or its major pro-apoptotic antagonist CHOP (CCAAT/enhancer binding protein homologous protein/GADD153) further established a critical role of the ER stress response system, where si-GRP78 sensitized cells to treatment with temozolomide, and si-CHOP provided protection from drug-induced toxicity. Thus, ER stress-regulatory components affect the chemotherapeutic response of glioblastoma cells to treatment with temozolomide, and inclusion of EGCG is able to increase the therapeutic efficacy of this DNA-damaging agent.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21257259     DOI: 10.1016/j.canlet.2010.11.008

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  28 in total

Review 1.  Targeting tumor ubiquitin-proteasome pathway with polyphenols for chemosensitization.

Authors:  Min Shen; Tak Hang Chan; Q Ping Dou
Journal:  Anticancer Agents Med Chem       Date:  2012-10-01       Impact factor: 2.505

Review 2.  Targeting Glioblastoma with the Use of Phytocompounds and Nanoparticles.

Authors:  Francesca Pistollato; Susanne Bremer-Hoffmann; Giuseppe Basso; Sandra Sumalla Cano; Iñaki Elio; Manuel Masias Vergara; Francesca Giampieri; Maurizio Battino
Journal:  Target Oncol       Date:  2016-02       Impact factor: 4.493

Review 3.  Drug resistance in glioblastoma: a mini review.

Authors:  Catherine P Haar; Preetha Hebbar; Gerald C Wallace; Arabinda Das; William A Vandergrift; Joshua A Smith; Pierre Giglio; Sunil J Patel; Swapan K Ray; Naren L Banik
Journal:  Neurochem Res       Date:  2012-01-10       Impact factor: 3.996

4.  The GLI1 splice variant TGLI1 promotes glioblastoma angiogenesis and growth.

Authors:  Hu Zhu; Richard L Carpenter; Woody Han; Hui-Wen Lo
Journal:  Cancer Lett       Date:  2013-09-15       Impact factor: 8.679

5.  EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition.

Authors:  Yong Zhang; Shao-Xiang Wang; Ji-Wei Ma; Hai-Ying Li; Jie-Cheng Ye; Si-Ming Xie; Bin Du; Xue-Yun Zhong
Journal:  J Neurooncol       Date:  2014-08-31       Impact factor: 4.130

6.  Natural product HTP screening for attenuation of cytokine-induced neutrophil chemo attractants (CINCs) and NO2- in LPS/IFNγ activated glioma cells.

Authors:  Elizabeth A Mazzio; David Bauer; Patricia Mendonca; Equar Taka; Karam F A Soliman
Journal:  J Neuroimmunol       Date:  2016-12-01       Impact factor: 3.478

7.  Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells.

Authors:  Chien-Ju Lin; Chin-Cheng Lee; Yung-Luen Shih; Chien-Huang Lin; Sheng-Hao Wang; Thay-Hsiung Chen; Chwen-Ming Shih
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

8.  The Hydroxyquinoline Analogue YUM70 Inhibits GRP78 to Induce ER Stress-Mediated Apoptosis in Pancreatic Cancer.

Authors:  Soma Samanta; Suhui Yang; Bikash Debnath; Ding Xue; Yuting Kuang; Kavya Ramkumar; Amy S Lee; Mats Ljungman; Nouri Neamati
Journal:  Cancer Res       Date:  2021-02-02       Impact factor: 13.312

9.  Repositioning of Verrucosidin, a purported inhibitor of chaperone protein GRP78, as an inhibitor of mitochondrial electron transport chain complex I.

Authors:  Simmy Thomas; Natasha Sharma; Reyna Gonzalez; Peng-Wen Pao; Florence M Hofman; Thomas C Chen; Stan G Louie; Michael C Pirrung; Axel H Schönthal
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

10.  A prospective study of dietary flavonoid intake and risk of glioma in US men and women.

Authors:  Alaina M Bever; Aedin Cassidy; Eric B Rimm; Meir J Stampfer; David J Cote
Journal:  Am J Clin Nutr       Date:  2021-10-04       Impact factor: 8.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.